Bollinger Ingeheim's new drug Arti-Cell® Forte to be listed in Europe

lameness is a common problem for horses and has an impact on their performance and animal welfareCurrent treatments cannot address the needs of all cases, and the industry is looking forward to innovative treatment options, so it is particularly focused on how to overcome the underlying causes beyond the symptomsrecently, Bollinger Ingeheim was listed in Europenew drug(http://Arti-Cell® Forte, to reduce mild recurrent lameness in horses caused by non-pusy joint infectionsArti-Cell® Forte treats lameness with specifically activated cartilage-induced stem cells, the first breakthrough treatmentdrug(http://approvedArti-Cell® Forte is a ready-to-use ultra-low temperature refrigerant formBollinger Ingerham partnered with Global Stem Cell Technology (GST) last year to provide new treatments and solutions to improve animalhealth(http://So Arti-Cell® Forte is a convenient, long-lasting (2) solution developed specifically for horse's limpingArti-Cell ® Forte has been approved to treat horse lameness after a scientific review by the EuropeanMedicines(http://Authority (2) and the European Commission's EU listing approvalthe(http://of theproduct will be available in Europe from May and June 2019